Trial Profile
A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Impact of a 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization With Vaccine Serotypes of Streptococcus Pneumoniae in Healthy Infants in Israel.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Feb 2020
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections; Streptococcal infections
- Focus Therapeutic Use
- Sponsors Pfizer
- 29 Jan 2020 Results (n=1754) of post-hoc analysis investigating the effect of acquisition of a range of commonly carried S.pneumoniae serotypes were published in the Clinical Infectious Diseases
- 13 Dec 2017 Results (n=1754) of a post-hoc analysis, published in the Vaccine.
- 10 Jan 2017 Results of a post-hoc analysis (n=1866) published in the Vaccine